MPSS

(redirected from Methylprednisolone sodium succinate)
Also found in: Dictionary, Medical.
Related to Methylprednisolone sodium succinate: Solumedrol
AcronymDefinition
MPSSMirror Polished Stainless Steel
MPSSMulti Point Signaling Server
MPSSModular Payload Support Structure
MPSSMassively Parallel Signature Sequencing
MPSSMission Planning and Scheduling System (US NASA)
MPSSMethylprednisolone Sodium Succinate
MPSSMultiple Page Size Support
MPSSMinistry of Public Safety and Security (Canada)
MPSSMainz Pain Staging System
MPSSMacpherson Secondary School (Singapore)
MPSSMIC (Many Integrated Core) Platform Software Stack (Intel)
MPSSManning Primary Safety System
MPSSMcKinnon Park Secondary School
MPSSMultipoint Signaling Server (Clarent)
MPSSMetropolitan Programs and Summer Sessions
MPSSMinnesota Physicians Support Services (program)
MPSSMilitary Personnel Support Staff (Canada)
MPSSManaged Premises Security Services
MPSSMulti Purpose Space Station
MPSSMarket Price Supply Service
MPSSMost Productive Software Size
MPSSMembers of Parliament Support Staff (UK)
MPSSMultiple Probes Spectrophotometer System
MPSSMigration Plan Support System
MPSSMicroprocessed Soldering System
MPSSMission Procurement Support System (Canada)
MPSSMicrosoft Product Support Services
MPSSManagement Programs and Services Staff
MPSSMulti-Service Provisioning Platform (Cisco)
MPSSMain Parachute Support Structure (NASA)
MPSSManipal Packaging Software Solutions (India)
References in periodicals archive ?
Effects of intrathecal injection of methylprednisolone sodium succinate on growth associated protein-43 expression in rats after acute spinal cord injury.
Does High Dose Methylprednisolone Sodium Succinate Really Improve Neurological Status in Patient With Acute Cervical Cord Injury?: A Prospective Study About Neurological Recovery and Early Complications.
On admission, she was treated with nebulized albuterol, methylprednisolone sodium succinate injection, and levofloxacin.
Hikma Pharmaceuticals PLC, the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (ANDA) for Methylprednisolone Sodium Succinate Injection USP, 500mg/vial and 1 gm/vial has been approved by the U.S.
In view of the escalation of symptoms and high CRP despite good compliance, the patient was admitted and given an infusion of methylprednisolone sodium succinate 30 mg/kg.